Literature DB >> 23997944

Targeted therapies in colorectal cancer: surgical considerations.

Carrie Luu1, Amanda K Arrington, Hans F Schoellhammer, Gagandeep Singh, Joseph Kim.   

Abstract

Colorectal cancer (CRC) is a leading worldwide health concern that is responsible for thousands of deaths each year. The primary source of mortality for patients with CRC is the development and subsequent progression of metastatic disease. The most common site for distant metastatic disease is the liver. Although patients with metastatic disease to the liver have several effective treatment options, the only one for cure remains surgical resection of the liver metastases. Historically, most patients with liver metastases have had unresectable disease, and only a small percentage of patients have undergone complete curative resection. However, improved systemic therapies have led to an evolution in strategies to treat metastatic CRC to the liver. Under most conditions the management of these patients remains complex; and as chemotherapy options and new targeted therapies continue to improve outcomes, it is clear that a multidisciplinary approach must be the foundation on which advanced surgical and medical techniques are employed. Here, in this review, we highlight the role of targeted therapies in the surgical management of patients with metastatic CRC to the liver.

Entities:  

Keywords:  Colorectal cancer (CRC); chemotherapy; liver; metastatic colorectal cancer (mCRC); surgical management; targeted therapies

Year:  2013        PMID: 23997944      PMCID: PMC3712295          DOI: 10.3978/j.issn.2078-6891.2013.032

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  71 in total

Review 1.  Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies.

Authors:  T Yau; P Chan; Y Ching Chan; B C Y Wong; R Liang; R J Epstein
Journal:  Aliment Pharmacol Ther       Date:  2008-03-20       Impact factor: 8.171

Review 2.  An update on the current and emerging targeted agents in metastatic colorectal cancer.

Authors:  Edward Chu
Journal:  Clin Colorectal Cancer       Date:  2011-07-12       Impact factor: 4.481

3.  Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections.

Authors:  J Figueras; F Burdio; E Ramos; J Torras; L Llado; S Lopez-Ben; A Codina-Barreras; S Mojal
Journal:  Ann Oncol       Date:  2007-04-13       Impact factor: 32.976

Review 4.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Authors:  Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Journal:  Eur J Cancer       Date:  2007-09-04       Impact factor: 9.162

5.  Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

Authors:  C Garufi; A Torsello; S Tumolo; G M Ettorre; M Zeuli; C Campanella; G Vennarecci; M Mottolese; I Sperduti; F Cognetti
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

Review 6.  CPT-11 (irinotecan) in the treatment of colorectal cancer.

Authors:  J P Armand; M Ducreux; M Mahjoubi; D Abigerges; R Bugat; G Chabot; P Herait; M de Forni; P Rougier
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

Review 7.  Targeted therapy for metastatic colorectal cancer: role of aflibercept.

Authors:  Edith P Mitchell
Journal:  Clin Colorectal Cancer       Date:  2012-10-24       Impact factor: 4.481

8.  Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study.

Authors:  Alessandro Ferrero; Luca Viganò; Roberto Polastri; Andrea Muratore; Haris Eminefendic; Daniele Regge; Lorenzo Capussotti
Journal:  World J Surg       Date:  2007-08       Impact factor: 3.352

9.  Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

Authors:  M Ychou; F Viret; A Kramar; F Desseigne; E Mitry; R Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-28       Impact factor: 3.333

10.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

View more
  12 in total

1.  Targeted therapies in colorectal cancer: the dos, don'ts, and future directions.

Authors:  Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Authors:  Shanthi Ganesh; Xue Shui; Kevin P Craig; Martin L Koser; Girish R Chopda; Wendy A Cyr; Chengjung Lai; Henryk Dudek; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

Review 3.  Optimal management of colorectal liver metastases in older patients: a decision analysis.

Authors:  Simon Yang; Shabbir M H Alibhai; Erin D Kennedy; Abraham El-Sedfy; Matthew Dixon; Natalie Coburn; Alex Kiss; Calvin H L Law
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

4.  Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways.

Authors:  Scott R Wheeler; Chanjuan Shi; Jonathan A Holt; Cindy L Vnencak-Jones
Journal:  J Gastrointest Oncol       Date:  2016-06

5.  Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.

Authors:  Seyung S Chung; Debbie Adekoya; Ikechukwu Enenmoh; Orette Clarke; Piwen Wang; Marianna Sarkyssian; Yong Wu; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.435

6.  Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis.

Authors:  I-Ming Kuo; Song-Fong Huang; Jy-Ming Chiang; Chien-Yuh Yeh; Kun-Ming Chan; Jinn-Shiun Chen; Ming-Chin Yu
Journal:  World J Surg Oncol       Date:  2015-03-04       Impact factor: 2.754

7.  Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.

Authors:  Seyung S Chung; Bryant Oliva; Sami Dwabe; Jaydutt V Vadgama
Journal:  Int J Oncol       Date:  2016-05-31       Impact factor: 5.650

8.  NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.

Authors:  Satya Narayan; Aruna S Jaiswal; Ritika Sharma; Akbar Nawab; Lizette Vila Duckworth; Brian K Law; Maria Zajac-Kaye; Thomas J George; Jay Sharma; Arun K Sharma; Robert A Hromas
Journal:  Oncotarget       Date:  2017-08-01

9.  DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.

Authors:  Parthasarathy Chandrakesan; Nathaniel Weygant; Randal May; Dongfeng Qu; Harisha R Chinthalapally; Sripathi M Sureban; Naushad Ali; Stan A Lightfoot; Shahid Umar; Courtney W Houchen
Journal:  Oncotarget       Date:  2014-10-15

10.  Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.

Authors:  Parthasarathy Chandrakesan; Jiannan Yao; Dongfeng Qu; Randal May; Nathaniel Weygant; Yang Ge; Naushad Ali; Sripathi M Sureban; Modhi Gude; Kenneth Vega; Eddie Bannerman-Menson; Lijun Xia; Michael Bronze; Guangyu An; Courtney W Houchen
Journal:  Mol Cancer       Date:  2017-02-01       Impact factor: 41.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.